Updates
Articles and notes
Programme news, documented milestones and explainers — clearly dated. Not announcements of new clinical results or fundraising totals.
Programme news
Dated notes about the programme itself. Announcements appear here only when there is a documented step to report.
The planned Phase 2B study — an overview
Plain-language note on the proposed design for NWPT-SM32300: who it is for, what it measures and what it does not claim. Not a results announcement.
How DeSci could help finance early-intervention research
Why conventional biotech finance often struggles with CHR-P timelines, and the platform path under evaluation. Nothing on this site is an offer.
Documented milestones
Only milestones with a dated record. Full list, statuses and sources: Study progress.
- Phase 1: first participants consented
- Phase 1: last study activity (14 healthy volunteers)
- Phase 2B: protocol finalisation reported as in progress; no completion date announced
- Phase 1: database locked
- Phase 1: analysis outputs delivered; results not yet published
No funding milestones have been published. Website publication dates are not clinical milestones.
Explainers
Evergreen background on the science and the clinical need, kept up to date. Educational — not announcements of new results.
Why early intervention matters
What clinical high risk for psychosis (CHR-P) means, current care standards, the transition estimates and their methods, and why earlier intervention remains a research priority. Field context only; not an efficacy claim for NWPT-SM32300.
What this programme aims to establish
What the CHR-P workstream is designed to learn — dose response, symptoms, safety and tolerability — and which questions remain open today.